2018-2019 Recently Appointed Professors

Appointed since May 14, 2018 through October 31, 2018

Faculty of Medicine reception held on December 10, 2018

Harold J. Burstein, M.D., Ph.D.

Dr. Burstein is Professor of Medicine at the Dana-Farber Cancer Institute. His clinical and research interests focus on improving treatments for breast cancer. Through clinical trials, scholarly commentary, leadership in evidence-based medicine, and innovative educational programs, he has helped define the standards of care for women with early- and late-stage breast cancer around the world.

Tanuja Chitnis, M.D.

Dr. Chitnis is Professor of Neurology at Mass General Hospital and Director of the Partners Pediatric Multiple Sclerosis Center and the Brigham and Women's Hospital CLIMB study, which follows over 2000 adult MS patients. She has developed the first clinical trials for children with MS resulting in the first FDA-approved drug for this disease. Her translational research is defining underlying factors contributing to the heterogeneity in MS disease course and novel therapeutic targets for demyelinating diseases.

Toni K. Choueiri, M.D.

Dr. Choueiri is Professor of Medicine at the Dana-Farber Cancer Institute where he is Director of the Lank Center for Genitourinary (GU) Oncology. He is a recognized leader in the clinical and translational studies of GU cancers and renal cell carcinoma (RCC). His work has led to the establishment of novel drugs and prognostic factors in advanced RCC, which are now widely used in clinical care.

Gregory J. Crosby, M.D., M.S.

Dr. Crosby is Professor of Anaesthesia at Brigham and Women's Hospital where he is Vice-Chair for Finance and Administration. He has devoted his career to assuring the well-being of the brain during and after surgery. His clinical expertise is in anesthetic management of the complex neurosurgical patient while his research has identified lasting adverse effects of anesthesia and surgery on the aging brain and clarified ways to reduce postoperative cognitive morbidity in geriatric surgical patients.

Daniel J. DeAngelo, M.D., Ph.D.
Dr. DeAngelo is Professor of Medicine at the Dana-Farber Cancer Institute and Chief of the Division of Leukemia. His clinical research focuses on optimizing therapy for adult leukemias, myelodysplastic syndromes and myeloproliferative disorders. He has a particular interest in the treatment of young adults with leukemia, particularly acute lymphoblastic leukemia.

David M. Dorfman, M.D., Ph.D.
Dr. Dorfman is Professor of Pathology at BWH where he is the Director of the Hematology Laboratory and Ambulatory Laboratories. He is an expert in laboratory hematology and the diagnosis of neoplasms of the hematopoietic and lymphoid tissues. His research focuses on identifying new diagnostic and prognostic markers and approaches for the characterization of these neoplasms and understanding disease pathogenesis.

Matthew J. Eagleton, M.D.
Dr. Eagleton is Professor of Surgery at Mass General Hospital where he is Chief of the Division of Vascular and Endovascular Surgery and Co-Director of the Fireman Vascular Center. He is recognized as a leader in the endovascular treatment of complex aortic disease. His work has contributed to developing technological and clinical pathways that shape treatment paradigms for aortic disease processes such as aortic dissection and aortic aneurysms.

Jason A. Efstathiou, M.D., D.Phil.
Dr. Efstathiou is Professor of Radiation Oncology at Mass General Hospital where he is Director of the Genitourinary (GU) Division and Clinical Co-Director of the Claire and John Bertucci Center for GU Cancers. He is a recognized leader in the field of GU malignancies and Radiation Oncology. His research has informed clinical guidelines and made novel contributions to organ preservation therapy for bladder cancer, technology assessment of proton beam therapy for prostate cancer, indications for and adverse effects of androgen deprivation therapy, and global oncology outreach efforts particularly in Botswana.

Timothy G. Ferris, M.D., M.P.H.
Dr. Ferris is Professor of Medicine at Mass General Hospital where he is Chief Executive Officer of the Mass General Physicians Organization. He pioneered the design and implementation of system-wide care delivery changes to improve patient health and reduce the healthcare cost burden, managing cost and quality of care for over 600,000 Medicare, Medicaid, and commercially insured patients under alternative payment models. His research has focused on healthcare quality measurement, risk adjustment, population health management, and health information technology, and has demonstrated how care coordination can reduce both costs and mortality among high-risk Medicare beneficiaries.

Jose C. Florez, M.D., Ph.D.
Dr. Florez is Professor of Medicine at Mass General Hospital where he is Chief of the Diabetes Unit. He and his group have contributed to the performance and analysis of high-throughput genomic studies in type 2 diabetes as well as related traits and their complications, in major pharmacogenetic clinical trials. He has used these genetic discoveries to help elucidate the genetic architecture of type 2 diabetes, understand disease heterogeneity, attain novel physiological insights, search for potential drug targets, and advance precision medicine.

Gad A. Getz, Ph.D.
Dr. Getz is Professor of Pathology at Mass General Hospital where he directs the Bioinformatics Program at the MGH Cancer Center and directs the Cancer Genome Computational Analysis group at the Broad. He is an internationally acclaimed leader in cancer genome analysis and is pioneering widely used cancer genome analysis tools. He has published numerous influential papers that describe new genes and pathways involved in different tumor types.

Joshua N. Goldstein, M.D., Ph.D.
Dr. Goldstein is Professor of Emergency Medicine at Mass General Hospital where he is Director of the Center for Neurologic Emergencies. His clinical research focuses on the diagnosis and early treatment of neurologic emergencies such as intracerebral hemorrhage and stroke. His work has developed new tools for personalized therapies in the acute setting and new therapies for emergency reversal of anticoagulation.

Laurie J. Goodyear, Ph.D., M.S.
Dr. Goodyear is Professor of Medicine at the Joslin Diabetes Center where she is Co-Head of the Section on Integrative Physiology and Metabolism. She investigates the molecular mechanisms that mediate the beneficial effects of exercise on chronic diseases, with a major focus on the effects of exercise to improve metabolic health. Her laboratory has made fundamental discoveries on exercise regulation of signaling pathways in skeletal muscle, most notably studies of AMPK, exercise-induced adaptations to adipose tissue controlling metabolic health, and a mechanism for the beneficial effects of maternal and paternal exercise on offspring health.

Arin K. Greene, M.D., M.M.Sc.
Dr. Greene is Professor of Surgery at Boston Children's Hospital where he is Director of the Lymphedema Program and Department of Plastic and Oral Surgery Laboratory. His clinical and research interests have focused on vascular anomalies and lymphedema. His work has led to the identification of somatic mutations in vascular anomalies that are being translated to the development of novel drug treatments, as well as the recognition that extreme obesity can cause lymphedema.

Robert I Haddad, M.D.
Dr. Haddad is Professor of Medicine at the Dana-Farber Cancer Institute where he is Chief of the Division of Head and Neck Oncology. His clinical and research interests focus on head and neck cancer with an emphasis on clinical trials and new drug development. His pioneering work in the field of neoadjuvant chemotherapy and immunotherapy has resulted in new and effective treatment options for patients.

Marcia C. Haigis, Ph.D.
Dr. Haigis is Professor of Cell Biology at Harvard Medical School. She is a leader in the field of mitochondrial biology and has made key contributions to our understanding of how mitochondria contribute to human diseases, such as cancer. Her studies have uncovered new metabolic vulnerabilities in cancer, including identifying new nodes of fat utilization in leukemia and elucidating the metabolic recycling of ammonia to generate amino acids important for tumor growth.

Kevin S. Hughes, M.D.
Dr. Hughes is Professor of Surgery at Mass General Hospital where he is Co-Director of the Avon Comprehensive Breast Evaluation Center and Medical Director of the Bermuda Cancer Genetics and Risk Assessment Clinic. He is a leader in the field of hereditary cancer. He uses his expertise in Health Information Technology to design and develop Clinical Decision Support tools that help clinicians better understand this exponentially growing field so that they can provide better care for their patients.

Judy W. Hung, M.D.
Dr. Hung is a Professor of Medicine at Mass General Hospital and Director of Adult Echocardiography and Director of the Trial Innovation Unit. Her research focus is on valvular heart disease and applying imaging techniques to understand cardiovascular physiology. Her achievements are in defining the mechanisms of common valvular heart disease with a focus on secondary mitral regurgitation using advanced noninvasive tools such as 3D echocardiography and flow convergence quantitative methods.

Jonathan C. Kagan, Ph.D.
Dr. Kagan is Professor of Pediatrics at Boston Children's Hospital. His research focuses on understanding the molecular basis of inflammation and host defense within diverse organisms. He is recognized for discovering the subcellular sites of pattern recognition receptor signal transduction and the subsequent effects of these signaling activities on innate and adaptive immunity.

Mannudeep K. Kalra, M.D.
Dr. Kalra is Professor of Radiology at Mass General Hospital where he is Director of the MGH Webster Center for Quality and Safety. His research focuses on CT radiation dose, techniques and applications of dual energy CT, and machine learning applications in thoracic imaging. This research has led to a better understanding and development of strategies for CT radiation dose and protocol optimization.

Sekar Kathiresan, M.D.
Dr. Kathiresan is Professor of Medicine at Mass General Hospital where he is Director of the Center for Genomic Medicine and the Director of Cardiovascular Disease Initiative at Broad Institute. He is a leader in investigating the genetics of complex diseases such as myocardial infarction. His research program has uncovered new mechanisms contributing to heart attack, highlighted triglyceride-rich lipoproteins as a therapeutic target, and developed a framework to interpret the genome for heart attack risk, which includes monogenic, somatic, and polygenic drivers of disease risk.

Salmaan Keshavjee, M.D., Ph.D.
Dr. Keshavjee is Professor of Global Health and Social Medicine at Harvard Medical School and Director of the HMS Center for Global Health Delivery—Dubai. With advanced training in both medicine and anthropology, he is a leading expert in drug-resistant tuberculosis treatment and the anthropology of health policy. He is also the author of Blind Spot: How neoliberalism infiltrated global health, which is based on research he conducted in Central Asia.

Gabriel Kreiman, Ph.D.
Dr. Kreiman is Professor of Ophthalmology at Boston Children's Hospital where he is Associate Director of the Center for Brains, Minds and Machines. His research focuses on elucidating how neural circuits compute and on building biologically inspired Artificial Intelligence systems. His findings have shed light on how neurons encode information about visual objects, and how we can teach computers to see the world the way humans do.

Anthony G. Letai, M.D., Ph.D.
Dr. Letai is Professor of Medicine at the Dana-Farber Cancer Institute. His basic research on apoptosis prompted his development of the BH3 profiling tool, which measures the readiness of cells to undergo apoptosis and has led to successful clinical trials of BCL-2 inhibitor drugs in chronic lymphocytic leukemia and acute myelogenous leukemia. His laboratory continues to study how rapid measurement of drug-induced signaling can identify personalized cancer drug regimens.

Ofer Levy, M.D., Ph.D.
Dr. Levy is Professor of Pediatrics at Boston Children's Hospital where he directs the Precisions Vaccine Program. This is a platform to foster international collaboration between academia, government and industry to employ human in vitro modeling, systems vaccinology and adjuvant discovery for development of vaccine formulations. His is working to identify innate immune pathway defects and create immunomodulatory therapies to prevent and treat infections found in vulnerable populations such as newborns and infants.

Hongbo R. Luo, Ph.D.
Dr. Luo is Professor of Pathology at Boston Children's Hospital where he is co-director of the Joint Program in Transfusion Medicine Research Program. His research focuses on intracellular signal networks that control the production, trafficking, function, and fate of neutrophils in infection and inflammation. His contributions have broad implications in innate immunity, neutrophil biology, and granulocyte transfusion.

Regina E. McGlinchey, Ph.D.
Dr. McGlinchey is Professor of Psychiatry at the VA Boston Healthcare System where she is Director of the VA Traumatic Brain Injury National Network Research Center and Associate Director for Research Training at the New England Geriatric Research, Education, and Clinical Center. She is recognized as a clinical neuroscience researcher, scholar, and teacher in the area of neurocognitive and neuroanatomical sequelae associated with aging, stroke, alcoholism, and military deployment-related trauma. She has pioneered research to understand the intermediate and long-term effects of trauma on the individual and has redefined the clinical boundaries that most impact functional outcome.

Jeffrey A. Meyerhardt, M.D., M.P.H.
Dr. Meyerhardt is Professor of Medicine at the Dana-Farber Cancer Institute where he is Clinical Director of the Gastrointestinal Cancer Center and Deputy Clinical Research Officer. He specializes in gastrointestinal cancers, and is an expert both in clinical trials for GI cancers as well as studies of energy balance in colorectal cancer. He has focused much of his research on questions of how host factors, including obesity, body composition, exercise, diet, and aspirin, are associated with the outcomes of survivors, showing significant associations for several factors that have led to ongoing interventional trials.

Richard N. Pierson III, M.D.
Dr. Pierson is Professor of Surgery at Mass General Hospital where he is Scientific Director of the Center for Transplantation Sciences. He is a recognized leader in the translation of transplantation tolerance approaches through primate heart allograft models, and in advancing cross-species “xenotransplantation”. In his current work on pig-to-baboon lung xenograft injury, recipient survival now exceeds one month, marking transformative progress toward successful use of cell and organ xenografts in various clinical applications.

Andrea L. Pusic, M.D.
Dr. Pusic is Professor of Surgery at the Brigham and Women’s Hospital where she is Chief of the Division of Plastic Surgery and co-Director of the Patient-Reported Outcomes, Value and Experience Center at Brigham Health. She is a recognized leader in patient-reported outcomes research. Her work has led to the development of condition-specific patient-reported outcomes measures for surgical patients, which are widely used nationally and internationally in clinical care, quality improvement, and research.

Francisco J. Quintana, Ph.D.
Dr. Quintana is Professor of Neurology at Brigham and Women's Hospital. His research combines advanced genomic and proteomic tools with innovative experimental models to study the regulation of the immune response in health and disease. This research has led to identifying candidate therapeutic targets for neurologic and inflammatory disorders.

Soumya Raychaudhuri, M.D., Ph.D.
Dr. Raychaudhuri is Professor of Medicine at Brigham and Women’s Hospital where he is the Director of the Center for Data Sciences. He is a clinical rheumatologist and accomplished statistical geneticist and computational biologist. His research currently focuses on integrating complex genomic and functional genomic data in order to better understand autoimmune and dramatic diseases.

Heidi L. Rehm, Ph.D.
Dr. Rehm is Professor of Pathology at Brigham and Women's Hospital and also serves as the Chief Genomic Officer in the Department of Medicine at Mass General Hospital. She is a recognized leader in the clinical interpretation of human genomes and setting standards for genomic medicine. She has a leadership role on a team that identifies the causes of rare disease and provides publicly accessible resources to support the clinical interpretation of genes and variants.

Nathan I. Shapiro, M.D., M.P.H.
Dr. Shapiro is Professor of Emergency Medicine at the Beth Israel Deaconess Medical Center where he is Vice Chair of Emergency Medicine Research. His research focuses on novel diagnostic and therapeutic approaches in sepsis. This includes identifying and studying new biomarkers for sepsis as well as developing a better understanding of optimal resuscitation strategies in severe sepsis and septic shock.

Kimberly Stegmaier, M.D.
Dr. Stegmaier is Professor of Pediatrics at the Dana-Farber Cancer Institute where she is Vice Chair of Pediatric Oncology Research and Co-director of the Pediatric Hematologic Malignancies Program. Her research focuses on the development and application of genomic approaches toward improving our understanding of the molecular underpinnings of pediatric malignancies as well as on identifying new pediatric cancer targets and small-molecule modulators. With an eye toward translation, her laboratory's research has advanced to clinical trials for both children and adults with cancer.

Christopher J. Sweeney, M.B.B.S.
Dr. Sweeney is Professor of Medicine at the Dana-Farber Cancer Institute where he is the co-leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program. He is a medical oncologist who has dedicated his career to treating and researching genitourinary malignancies. His research has provided new insights into the biology and clinical management of prostate cancer and germ cell tumors.

David R. Walt, Ph.D.

Dr. Walt is Professor of Pathology at Brigham and Women's Hospital and a Core Faculty Member at the Wyss Institute. His research focuses on using micro and nanotechnologies to develop ultrasensitive diagnostics applied to pressing clinical needs. He has developed multiple widely used genomic and proteomic technologies that have led to fundamental discoveries and translational applications across many different diseases, including oncology, neurology, and infectious disease.